Adam B Polis


Affiliation: Merck Research Laboratories
Country: USA


  1. Ambegaonkar B, Tipping D, Polis A, Tomassini J, Tershakovec A. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237:829-37 pubmed publisher
    ..Adding ezetimibe to ongoing statin therapy appeared to be an effective option for patients who do not achieve lipid-lowering goals on statins alone. ..
  2. Davidson M, Tomassini J, Jensen E, Neff D, Polis A, Tershakovec A. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016;246:121-9 pubmed publisher
    ..These trends are consistent with increased treatment and control of high LDL-C levels over recent years in clinical practice, and may influence the results of cIMT studies. ..